ORDONEZ KATHY 4

What Happened Kathy Ordonez, a director of Pacific Biosciences of California, Inc. (PACB), received a derivative award on 2026-06-03 for 223,492 shares (reported as an acquisition at $0.00). The Form 4 classifies this as a grant/award (transaction code A); the filing reports $0 aggregate value because the award is a derivative (option-like) grant rather than an open-market purchase.

Key Details

• Transaction date: 2026-06-03; Form 4 filed 2026-06-04 (timely).
• Shares granted: 223,492 (derivative award) at $0.00 per share; aggregate reported value $0.
• Vesting: The award vests monthly over one year (see footnote F1). Vesting may accelerate to the next annual meeting if earlier, provided she remains a director.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Transaction type/code: A = Grant/Award (derivative securities).

Context This was a compensation grant of derivative securities (an option-like award) rather than an open-market purchase or sale. The shares are subject to a vesting schedule and were not immediately sold; such grants are common for board compensation and align long-term incentives with shareholders but do not by themselves indicate the insider’s view of near-term stock performance.